Peroxisome proliferator-activated receptors: Regulation of transcriptional activities and roles in inflammation

Journal of Steroid Biochemistry and Molecular Biology

Volumn 85, Issue 2-5, 2003, Pages 267-273

  Blanquart, Christophe ^a   Barbier, Olivier ^a   Fruchart, Jean Charles ^a   Staels, Bart ^a   Glineur, Corine ^a  

^a NONE

Author keywords

Phosphorylation; Transcription factors; Ubiquitination and inflammation

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEASOME; STAT1 PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT;

BINDING SITE; CELL LEVEL; CELL MIGRATION; CONFERENCE PAPER; CYTOKINE PRODUCTION; DEGRADATION; DNA BINDING; DNA SEQUENCE; ENVIRONMENTAL FACTOR; HUMAN; INFLAMMATION; NONHUMAN; PHOSPHORYLATION; PROMOTER REGION; PROTEIN CONTENT; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; RNA TRANSLATION; TRANSCRIPTION REGULATION;

EID: 0041887308     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00214-0     Document Type: Conference Paper

References (51)

1. Barbier O., Pineda Torra I., Duguay Y., Blanquart C., Fruchart J.C., Glineur C., Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22(5):2002;717-726.
2. Aranda A., Pascual A. Nuclear hormone receptors and gene expression. Physiol. Rev. 81(3):2001;1269-1304.
3. Kliewer S., Umesono K., Noonan D.J., Heyman R.A., Evans R.M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature (London). 358(6389):1992;771-774.
4. Gampe R.T., Montana V.G., Lambert M.H., Miller A.B., Bledsoe R.K., Milburn M.V., Kliewer S.A., Willson T.M., Xu H.E. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell. 5(3):2000;545-555.
5. Bourguet W., Germain P., Gronemeyer H. Nuclear receptor ligand-binding domains: three-dimensional structures. Trends Pharmacol. Sci. 21(10):2000;381-388.
6. Fruchart J.C., Duriez P., Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin. Lipidol. 10(3):1999;245-257.
7. Willson T.M., Brown P.J., Sternbach D.D., Henke B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43(4):2000;527-550.
8. Oliver W.R. Jr., Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., Lewis M.C., Winegar D.A., Sznaidman M.L., Lambert M.H., Xu H.E., Sternbach D.D., Kliewer S.A., Hansen B.C., Willson T.M. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U.S.A. 98(9):2001;5306-5311.
9. Darimont B.D., Wagner R.L., Apriletti J.W., Stallcup M.R., Kushner P.J., Baxter J.D., Fletterick R.J., Yamamoto K.R. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. 12(21):1998;3343-3356.
10. Xu H.E., Stanley T.B., Montana V.G., Lambert M.H., Shearer B.G., Cobb J.E., McKee D.D., Galardi C.M., Plunket K.D., Nolte R.T., Parks D.J., Moore J.T., Kliewer S.A., Willson T.M., Stimmel J.B. Structural basis for antagonist-mediated recruitment of nuclear co- repressors by PPARalpha. Nature (London). 415(6873):2002;813-817.
11. Shalev A., Siegrist-Kaiser C.A., Yen P.M., Wahli W., Burger A.G., Chin W.W., Meier C.A. The peroxisome proliferator-activated receptor alpha is a phosphoprotein: regulation by insulin. Endocrinology. 137(10):1996;4499-4502.
12. Juge-Aubry C.E., Hammar E., Siegrist-Kaiser C., Pernin A., Takeshita A., Chin W.W., Burger A.G., Meier C.A. Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent trans-activating domain. J. Biol. Chem. 274(15):1999;10505-10510.
13. Barger P.M., Browning A.C., Garner A.N., Kelly D.P. p38 mitogen-activated protein kinase activates peroxisome proliferator-activated receptor alpha: a potential role in the cardiac metabolic stress response. J. Biol. Chem. 276(48):2001;44495-44501.
14. Lazennec G., Canaple L., Saugy D., Wahli W. Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. Mol. Endocrinol. 14(12):2000;1962-1975.
15. Martin G., Duez H., Blanquart C., Berezowski V., Poulain P., Fruchart J.C., Najib-Fruchart J., Glineur C., Staels B. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J. Clin. Invest. 107(11):2001;1423-1432.
16. Zhang B., Berger J., Zhou G., Elbrecht A., Biswas S., White-Carrington S., Szalkowski D., Moller D.E. Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 271(50):1996;31771-31774.
17. Hu E., Kim J.B., Sarraf P., Spiegelman B.M. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science. 274(5295):1996;2100-2103.
18. Adams M., Reginato M.J., Shao D., Lazar M.A., Chatterjee V.K. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen- activated protein kinase site. J. Biol. Chem. 272(8):1997;5128-5132.
19. Camp H.S., Tafuri S.R., Leff T. c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-γ1 and negatively regulates its transcriptional activity. Endocrinology. 140:1999;392-397.
20. Shao D., Rangwala S.M., Bailey S.T., Krakow S.L., Reginato M.J., Lazar M.A. Interdomain communication regulating ligand binding by PPAR-gamma. Nature (London). 396(6709):1998;377-380.
21. Camp H.S., Tafuri S.R. Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J. Biol. Chem. 272(16):1997;10811-10816.
22. Han J., Hajjar D.P., Tauras J.M., Feng J., Gotto A.M. Jr., Nicholson A.C. Transforming growth factor-beta1 (TGF-beta1) and TGF-beta2 decrease expression of CD36, the type B scavenger receptor, through mitogen- activated protein kinase phosphorylation of peroxisome proliferator- activated receptor-gamma. J. Biol. Chem. 275(2):2000;1241-1246.
23. Hansen J.B., Zhang H., Rasmussen T.H., Petersen R.K., Flindt E.N., Kristiansen K. Peroxisome proliferator-activated receptor delta (PPARdelta)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling. J. Biol. Chem. 276(5):2001;3175-3182.
24. Krogsdam A.M., Nielsen C.A., Neve S., Holst D., Helledie T., Thomsen B., Bendixen C., Mandrup S., Kristiansen K. Nuclear receptor corepressor-dependent repression of peroxisome- proliferator-activated receptor delta-mediated transactivation. Biochem. J. 363(Pt 1):2002;157-165.
25. Mimnaugh E.G., Bonvini P., Neckers L. The measurement of ubiquitin and ubiquitinated proteins. Electrophoresis. 20(2):1999;418-428.
26. Hodges M., Tissot C., Freemont P.S. Protein regulation: tag wrestling with relatives of ubiquitin. Curr. Biol. 8(21):1998;R749-752.
27. Hauser S., Adelmant G., Sarraf P., Wright H.M., Mueller E., Spiegelman B.M. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J. Biol. Chem. 24(Jun):2000;18527-18533.
28. Blanquart C., Barbier O., Fruchart J.C., Staels B., Glineur C. Peroxisome proliferator-activated receptor alpha (PPARalpha) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes. J. Biol. Chem. 277(40):2002;37254-37259.
29. Floyd Z.E., Stephens J.M. Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes. J. Biol. Chem. 277(6):2002;4062-4068.
30. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature (London). 384(6604):1996;39-43.
31. Staels B., Koenig W., Habib A., Merval R., Lebret M., Pineda Torra I., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J., Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature (London). 393(6687):1998;790-793.
32. Madej A., Okopien B., Kowalski J., Zielinski M., Wysocki J., Szygula B., Kalina Z., Herman Z.S. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int. J. Clin. Pharmacol. Ther. 36(6):1998;345-349.
33. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 106(6):2002;679-684.
34. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 274(45):1999;32048-32054.
35. Poynter M.E., Daynes R.A. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J. Biol. Chem. 273(49):1998;32833-32841.
36. Kockx M., Gervois P.P., Poulain P., Derudas B., Peters J.M., Gonzalez F.J., Princen H.M., Kooistra T., Staels B. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood. 93(9):1999;2991-2998.
37. Gervois P., Vu-Dac N., Kleemann R., Kockx M., Dubois G., Laine B., Kosykh V., Fruchart J.C., Kooistra T., Staels B. Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. J. Biol. Chem. 276(36):2001;33471-33477.
38. Delerive P., Gervois P., Fruchart J.C., Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J. Biol. Chem. 275(47):2000;36703-36707.
39. Marx N., Sukhova G.K., Collins T., Libby P., Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 99(24):1999;3125-3131.
40. Pasceri V., Wu H.D., Willerson J.T., Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 101:2000;235-238.
41. Delerive P., Martin F., Chinetti G., Trottein F., Fruchart J.C., Najib J., Duriez P., Staels B. PPAR activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the AP-1 signalling pathways. Circ. Res. 85:1999;394-402.
42. Marx N., Kehrle B., Kohlhammer K., Grub M., Koenig W., Hombach V., Libby P., Plutzky J. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ. Res. 90(6):2002;703-710.
43. Kleemann R., Gervois P.P., Verschuren L., Staels B., Princen H.M., Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκ B-C/EBP-β complex formation. Blood. 101(2):2003;545-551.
44. Su C.G., Wen X., Bailey S.T., Jiang W., Rangwala S.M., Keilbaugh S.A., Flanigan A., Murthy S., Lazar M.A., Wu G.D. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J. Clin. Invest. 104(4):1999;383-389.
45. Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., Glass C.K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106(4):2000;523-531.
46. Thieringer R., Fenyk-Melody J.E., Le Grand C.B., Shelton B.A., Detmers P.A., Somers E.P., Carbin L., Moller D.E., Wright S.D., Berger J. Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. J. Immunol. 164(2):2000;1046-1054.
47. Chung S.W., Kang B.Y., Kim S.H., Pak Y.K., Cho D., Trinchieri G., Kim T.S. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-κ B. J. Biol. Chem. 275(42):2000;32681-32687.
48. Law R.E., Meehan W.P., Xi X.P., Graf K., Wuthrich D.A., Coats W., Faxon D., Hsueh W.A. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J. Clin. Invest. 98(8):1996;1897-1905.
49. Li M., Pascual G., Glass C.K. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell. Biol. 20(13):2000;4699-4707.
50. Yang X.Y., Wang L.H., Chen T., Hodge D.R., Resau J.H., DaSilva L., Farrar W.L. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J. Biol. Chem. 275(7):2000;4541-4544.
51. Duval C., Chinetti G., Trottein F., Fruchart J.C., Staels B. The role of PPARs in atherosclerosis. Trends Mol. Med. 8(9):2002;422-430.